Akoustis Technologies Inc. (AKTS)
NASDAQ (CM) NASDAQ (CM) Primary 
Aktis Oncology: Padcev Is Building The Market It Wants
Aktis Oncology is undervalued, trading below IPO price despite robust cash reserves and two independent clinical programs. AKTS has a cash runway into 2029, supported by $517.3M in cash and a $1.2B+ partnership with Eli Lilly, minimizing near-term dilution risk. AKY-1189 and AKY-2519 offer differentiated radiopharma approaches, with Fast Track status and early human dosimetry data de-risking development.
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.
Aktis Oncology: Mini-Proteins With A Targeted Punch
Aktis Oncology trades at a $1.1B market cap with $540M cash, pricing its pipeline and Eli Lilly collaboration at $560M. The investment thesis hinges on the mini-protein platform targeting Nectin-4, with lead asset AKY-1189's Phase Ib data expected Q1 2027 as a binary catalyst. My conservative base case yields $12/share equity value, well below the ~$20 market price, implying patient expansion is already priced in.
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting
Aktis Oncology is initiated with a "Buy" rating, driven by its innovative miniprotein radioconjugates targeting Nectin-4 and B7-H3 solid tumors. The company expects key catalysts: AKY-1189 phase 1b Part 1 data in Q1 2027 and AKY-2519 ASCO poster presentations and phase 1b initiation in mid-2026. The company's approach aims to expand the radiopharmaceutical market beyond PSMA and SSTR2, leveraging alpha-emitting actinium-225 for broader tumor targeting potential.
Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's What You Should Know
The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
2 Radio Frequency Stocks to Watch in a Challenging Industry
The accelerated deployment of 5G is enhancing the prospects of the Zacks Semiconductors - Radio Frequency industry players like RF Industries (RFIL) and Akoustis Technologies (AKTS) despite challenging macroeconomic conditions.
2 Radio Frequency Stocks to Watch in a Challenging Industry
The accelerated deployment of 5G is enhancing the prospects of the Zacks Semiconductors - Radio Frequency industry players like RF Industries (RFIL) and Akoustis Technologies (AKTS) despite challenging macroeconomic conditions.
3 Stocks No One in Their Right Mind Would Own Right Now: June Edition
Steer clear of stocks to avoid in order to effectively protect your investment portfolio. Moreover, the essence of investing is identifying the next high-flying stock and knowing which stocks to avoid.
3 Penny Stocks That Could Turn Your $1 Into a Windfall
There's no denying that penny stocks with high potential carry incredibly big risks. At the same time, that's why they're so appealing.
Why Is Akoustis Technologies (AKTS) Stock Up 158% Today?
Akoustis Technologies (NASDAQ: AKTS ) stock is rocketing higher on Wednesday alongside the rollout of design updates from the radio frequency ( RF ) filter manufacturing company. Akoustis Technologies notes that it has redesigned its XBAW manufacturing process.
